open access

Ahead of Print
Research paper
Published online: 2021-12-28
Get Citation

Adipocyte related peptides — galanin and resistin in endometrioid type endometrium cancer

Sumeyra Nergiz Avcıoğlu1, Hasan Yüksel1
DOI: 10.5603/GP.a2021.0229
·
Pubmed: 35072231
Affiliations
  1. Adnan Menderes University Faculty of Medicine Department of Obstetrics and Gynecology Aydın, Turkey, Turkey

open access

Ahead of Print
ORIGINAL PAPERS Gynecology
Published online: 2021-12-28

Abstract

Objectives: The aim of (this) study was to investigate concentrations of galanin and resistin in patients with endometrioid type endometrium cancer.

Material and methods: A total of 85 patients (52 Endometrioid type Endometrium Cancer patients and 33 healthy controls) were included in the study. Serum galanin and resistin levels were measured by an enzyme-linked immunosorbent assay (ELISA).

Results: It was found that the sensitivity and specificity of galanin at the cut off level of 0,37 ng/mL, was 82.96% and 68.78% respectively (AUC = 0.795, CI:0.691-0.898, p < 0.001). Sensitivity and specificity of resistin at the 0.27 ng/mL cut off level, was found to be 82.95% and 59.12% respectively (AUC = 0.705, CI:0.588-0.822, p < 0.001) for prediction of endometrioid type endometrium cancer diagnosis. Bivariate logistic regression analysis showed that, increased galanin concentration, greater than 0.37 ng/mL, increased the risk of having endometrioid type endometrium cancer 10.2 times (95% CI: 3.425-30.881, p < 0.001) and resistin concentration > 0.27 ng/mL, increased the risk of having endometrioid type endometrium cancer 5.6 fold (95% CI: 1.939-16.282, p = 0.001). On the other hand, according to adjusted Odds Ratio results of the multiple logistic regression analysis, effect of interaction between galanin and resistin on having endometrioid type endometrium cancer was statistically significant. Increased galanin concentration > 0.37 ng/mL with increased resistin concentration > 0.27 ng/mL had adjusted Odds Ratio = 27.182 times greater risk of having endometrioid type endometrium cancer (95% CI: 6.653 to 111.109, p < 0.001).

Conclusions: Increased galanin and resistin levels, either separately or together with, seemed to increase the risk of endometrioid type endometrium cancer other than different risk factors.

Abstract

Objectives: The aim of (this) study was to investigate concentrations of galanin and resistin in patients with endometrioid type endometrium cancer.

Material and methods: A total of 85 patients (52 Endometrioid type Endometrium Cancer patients and 33 healthy controls) were included in the study. Serum galanin and resistin levels were measured by an enzyme-linked immunosorbent assay (ELISA).

Results: It was found that the sensitivity and specificity of galanin at the cut off level of 0,37 ng/mL, was 82.96% and 68.78% respectively (AUC = 0.795, CI:0.691-0.898, p < 0.001). Sensitivity and specificity of resistin at the 0.27 ng/mL cut off level, was found to be 82.95% and 59.12% respectively (AUC = 0.705, CI:0.588-0.822, p < 0.001) for prediction of endometrioid type endometrium cancer diagnosis. Bivariate logistic regression analysis showed that, increased galanin concentration, greater than 0.37 ng/mL, increased the risk of having endometrioid type endometrium cancer 10.2 times (95% CI: 3.425-30.881, p < 0.001) and resistin concentration > 0.27 ng/mL, increased the risk of having endometrioid type endometrium cancer 5.6 fold (95% CI: 1.939-16.282, p = 0.001). On the other hand, according to adjusted Odds Ratio results of the multiple logistic regression analysis, effect of interaction between galanin and resistin on having endometrioid type endometrium cancer was statistically significant. Increased galanin concentration > 0.37 ng/mL with increased resistin concentration > 0.27 ng/mL had adjusted Odds Ratio = 27.182 times greater risk of having endometrioid type endometrium cancer (95% CI: 6.653 to 111.109, p < 0.001).

Conclusions: Increased galanin and resistin levels, either separately or together with, seemed to increase the risk of endometrioid type endometrium cancer other than different risk factors.

Get Citation

Keywords

galanin; resistin; adipose tissue; endometrioid type endometrium cancer

About this article
Title

Adipocyte related peptides — galanin and resistin in endometrioid type endometrium cancer

Journal

Ginekologia Polska

Issue

Ahead of Print

Article type

Research paper

Published online

2021-12-28

Page views

421

Article views/downloads

152

DOI

10.5603/GP.a2021.0229

Pubmed

35072231

Keywords

galanin
resistin
adipose tissue
endometrioid type endometrium cancer

Authors

Sumeyra Nergiz Avcıoğlu
Hasan Yüksel

References (35)
  1. Banas T, Juszczyk G, Pitynski K, et al. Incidence and mortality rates in breast, corpus uteri, and ovarian cancers in Poland (1980-2013): an analysis of population-based data in relation to socioeconomic changes. Onco Targets Ther. 2016; 9: 5521–5530.
  2. Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013; 105(15): 1142–1150.
  3. Housa D, Vernerova Z, Heracek J, et al. Adipocytokines and cancer. Physiol Res. 2006; 55(3): 233–244.
  4. Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol. 2014; 20(24): 7941–7949.
  5. Fang PH, Yu M, Ma YP, et al. Central nervous system regulation of food intake and energy expenditure: role of galanin-mediated feeding behavior. Neurosci Bull. 2011; 27(6): 407–412.
  6. Uehara T, Kanazawa T, Mizukami H, et al. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci. 2014; 105(1): 72–80.
  7. El-Salhy M, Tjomsland V, Theodorsson E. Effects of triple treatment with octreotide, galanin and serotonin on a human pancreas cancer cell line in xenografts. Histol Histopathol. 2005; 20: 745–752.
  8. Doufekas K, Hadwin R, Kandimalla R, et al. GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. Int J Gynecol Cancer. 2013; 23(6): 1050–1055.
  9. Asgary S, SamsamShariat SZ, Ghorbani A, et al. Relationship between serum resistin concentrations with metabolic syndrome and its components in an Iranian population. Diabetes Metab Syndr. 2015; 9(4): 266–270.
  10. Aquilante CL, Kosmiski LA, Knutsen SD, et al. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008; 57(4): 494–501.
  11. Dalamaga M. Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets. World J Exp Med. 2013; 3(3): 34–42.
  12. Radikova Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocr Regul. 2003; 37(3): 189–194.
  13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  14. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009; 105(2): 109.
  15. Hlavna M, Kohut L, Lipkova J, et al. Relationship of resistin levels with endometrial cancer risk. Neoplasma. 2011; 58(2): 124–128.
  16. Bu Le, Liu Z, Zou J, et al. Blocking central galanin receptors attenuates insulin sensitivity in myocytes of diabetic trained rats. J Neurosci Res. 2013; 91(7): 971–977.
  17. Manabe T, Okada Y, Sawai H, et al. Effect of galanin on plasma glucose, insulin and pancreatic glucagon in dogs. J Int Med Res. 2003; 31(2): 126–132.
  18. Fang P, Yu M, Guo L, et al. Galanin and its receptors: a novel strategy for appetite control and obesity therapy. Peptides. 2012; 36(2): 331–339.
  19. Azuma K, Katsukawa F, Oguchi S, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res. 2003; 11(8): 997–1001.
  20. Dalamaga M, Sotiropoulos G, Karmaniolas K, et al. Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013; 46(7-8): 584–590.
  21. Chen CC, Li TC, Li CI, et al. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism. 2005; 54(4): 471–475.
  22. Matsuda M, Kawasaki F, Yamada K, et al. Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. Diabet Med. 2004; 21(8): 881–888.
  23. Bauer S, Neumeier M, Wanninger J, et al. Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J Diabetes Complications. 2011; 25(6): 377–381.
  24. Utzschneider KM, Carr DB, Tong J, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia. 2005; 48(11): 2330–2333.
  25. Ntikoudi E, Kiagia M, Boura P, et al. Hormones of adipose tissue and their biologic role in lung cancer. Cancer Treat Rev. 2014; 40(1): 22–30.
  26. Abate N, Sallam HS, Rizzo M, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014; 20(31): 4961–4969.
  27. Singh AK, Tiwari S, Gupta A, et al. Association of resistin with metabolic syndrome in Indian subjects. Metab Syndr Relat Disord. 2012; 10(4): 286–291.
  28. Oh KiW, Lee WY, Rhee EJ, et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf). 2005; 63(2): 131–138.
  29. Norata GD, Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007; 156(2): 279–284.
  30. Matkowskyj K, Royan SV, Blunier A, et al. Age-dependent differences in galanin-dependent colonic fluid secretion after infection with Salmonella typhimurium. Gut. 2009; 58(9): 1201–1206.
  31. Ozgor BY, Iyibozkurt C, Bastu E, et al. Investigation of resistin 420 and 62 gene polymorphism in patients with endometrial cancer. Taiwan J Obstet Gynecol. 2019; 58(1): 164–167.
  32. Kanazawa T, Kommareddi PK, Iwashita T, et al. Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells. Clin Cancer Res. 2009; 15(7): 2222–2230.
  33. Gilaberte Y, Vera J, Coscojuela C, et al. Expression of Galanin in Melanocytic Tumors. Actas Dermo-Sifiliográficas (English Edition). 2007; 98(1): 24–34.
  34. Tsai CH, Tsai HC, Huang HN, et al. Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget. 2015; 6(1): 258–270.
  35. Wallace AE, Gibson DA, Saunders PTK, et al. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010; 206(2): 141–157.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl